


## A Discussion of AMD and Statins

Todd A. Zelczak, OD, FAAO  
Midwest Optometric Society



## Age-Related Macular Degeneration Review

- Affects over 150 million people worldwide
- Leading cause of vision loss in developed countries
- Prevalence increasing due to increased life expectancy
- Worldwide projected cost of vision loss due to AMD in 2020 is predicted to be approx. \$392 billion
- Prevalence:
  - Dry (85%)
  - Wet (15%)
- Genetics vs Environmental factors

## Risk Factors Associated with AMD

- Age
- Smoking
- Family history
- Gender
- Race
- UV exposure
- Diet
- Obesity
- Hypertension
- Eye color



## Current Treatment Options for AMD

- Wet AMD (15%)
  - Injections with angiogenesis inhibitors (VEGF)
  - Photodynamic Therapy
  - Laser surgery
- PROBLEM:
  - Disease and loss of vision may progress despite treatment
  - Sustainability

## Current Treatment Options for AMD

### ► Dry AMD(85%)

Early and Intermediate stage  
Vitamin supplementation (AREDS)  
Lifestyle/Environmental

### ► Problem:

Prevention vs treatment?  
Science on supplementation still controversial  
No form of treatment available (advanced stage)

**\*\*Lack of effective treatment available for non-exudative AMD(85%)**


## Pathogenesis of AMD

6 Major Pathways

1. Age
2. Lipid and lipoprotein metabolism and transport
3. Inflammation and immunity
4. Extracellular matrix and cell adhesion
5. Angiogenesis
6. Cellular stress and toxicity


Adapted from Miller JW. Age-related Macular Degeneration-Piecing the Puzzle: The LXIX Edward Jackson Memorial Lecture. *Amer J Ophthalmol* 2013; 155, 1-35. e13

## Normal Macular Structure




## Dry AMD


Lipid Transport and Metabolism




### Progression of Dry AMD Inflammation and Immunity




### Pathogenesis of Wet AMD Angiogenesis



### Progression of AMD Advanced Atrophic AMD



### Intermediate-Late Stage Dry AMD Discrete and Large Confluent Drusen Drusenoid Pigment Epithelial Detachments



### Late-Stage Dry AMD Geographic Atrophy



### Late-Stage Wet AMD Disciform Scar



### Link Between Cardiovascular Disease and AMD


### Cardiovascular Risk Factors Associated with AMD Development and Progression<sup>1,2</sup>

- Smoking
- Hypertension
- Serum lipid levels
- Shared susceptibility genes

<sup>1</sup> Yip, J.L., Khawaja, A.P., Chan, M.P. et al. Cross sectional and longitudinal associations between cardiovascular risk factors and age related macular degeneration in the EPIC-Norfolk eye study. *PLoS One*. 2015; 10: e0132565

<sup>2</sup> Miller, J.W. Age-related macular degeneration revisited—piecing the puzzle: the LXX Edward Jackson memorial lecture. *Am. J. Ophthalmol.* 2013; 155: 1–35 e13


## Dry AMD and Atherosclerosis



Could Statin Treatment Have an Affect on AMD Status or Progression?

## Statins

- Inhibit HMG-CoA reductase
- Reduces cholesterol synthesis
- Increase liver LDL receptor levels
- Decrease serum LDL, triglycerides
- Increase serum HDL
- Antioxidant properties



Epidemiological Studies Involving Statins and AMD

- Gehlbach et al., 2015: "...evidence is insufficient to conclude if statins have a role in preventing, delaying the onset, or progression of AMD."
- Guymer et al., 2013: "...a small placebo-controlled study ...suggested that 40mg of simvastatin may slow the progression of early/intermediate AMD..."
- Vanderbeek et al., 2013: "...found that statin use for more than a year was associated with increased hazard for neovascular AMD"
- Klein et al., 2014: "over a 20-year follow-up period did not show a significant association between lipid levels or lipid pathway genes with the incidence or progression of AMD"

### Limitations of Previous AMD/Statin Studies

- Large heterogeneity of AMD
- Lack of standardization of statin dosage
- Lack of standardization of lipophilicity
- Small samples sizes
- Retrospective biases

### High Dose Statin Cardiovascular Studies

- PROVE-IT Study
- REVERSAL Trials
- ASTEROID Trials
- Others

### Case Report


- 63yo wm with hx dry AMD/AREDS supple
- Presented for second opinion due to deteriorating vision
- Baseline VA 20/25 OU w distortion
- Fundus: Extensive large confluent soft drusen w pig alterations
- SD-OCT: Significant drusenoid PEDs w distortion of overlying RPE/photo

■ Plan: Continue AREDS supple, monitor fundus/VA

■ 1 year Results: VA decreased to 20/30 OU, increased distortion

1 Demetrios G. Vavvas et al. Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine, March 2016, Volume 5, Pages 198-203



1 Demetrios G. Vavvas et al. Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine, March 2016, Volume 5, Pages 198-203



### New Treatment Plan

Initial Case Report

- High-dose Atorvastatin
- 10mg/day initial dose gradually increased to 80mg/day over 9 mos
- Results reported 6 mos after reaching target dose



## Pilot Study

Mass Eye and Ear, Boston, USA  
University of Crete, Heraklion, Greece

- Objective:** To study the effects of **high-dose statins**, similar to those showing regression of atherosclerotic plaques, in AMD
- Design:** Multicenter clinical study of 26 patients. Pts received 80 mg of atorvastatin daily and were monitored at baseline and every 3 months with best corrected VA, fundus photographs, OCT, and blood work
- Enrollment Criteria:** >50 years of age, diagnosis of AMD and presence of large soft confluent drusen (drusenoid PED's); no or minimal GA; no choroidal neovascularization

1 Demetrios G. Vavvas et al. Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine. March 2016, Volume 5, Pages 198-203

## Results of Pilot Study

Mass Eye and Ear, Boston, USA  
University of Crete, Heraklion, Greece

- 26 subjects enrolled with 3 discontinuing because of cramps (1), muscle aches (1), and hair loss (1)
- 23 subjects completed a minimum follow-up of 12 mos (avg 16 mos)
- 10 of 23 subjects showed significant regression of drusen deposits (8 showing almost complete regression)
- Responders showed avg VA gain of 3 letters
- Avg time to respond was 11.7 mos (range 3-22 mos)

## Results of Pilot Study

Mass Eye and Ear, Boston, USA  
University of Crete, Heraklion, Greece

- Previously drusenoid PED regression has been accompanied by atrophy and vision loss
- In this Pilot Study we observed regression of drusen and drusenoid PEDs with vision gain and without atrophy
- No cases progressed to neovascular AMD

## Characteristics of Responders vs Non-Responders


	All (n=23)	Responders (n=10)	Non-Responders (n=13)	
Age	68.1 ± 6	70.6 ± 6.2	66.2 ± 5.5	p = 0.08137
Hypertension	10	5/10	5/13	Fisher 0.685018
Initial Cholesterol (total chol mg/dL)	208 ± 34.9	210 ± 33.4	207 ± 37.4	p = 0.859484
Last Cholesterol	147 ± 31	161 ± 34.2	136 ± 24.4	p = 0.057162
Chol. Reduction	-62 ± 35	-49 ± 31.2	-71 ± 35.9	p = 0.140764
Eye Vitamins	14	7/10	7/13	Fisher 0.669269
Vitamin D Use	5	3/10	2/13	Fisher 0.635117
Fish Oil Use	5	2/10	3/13	Fisher 1
Aspirin Use	7	3/10	4/13	Fisher 1
Initial VA (letters)	77.6 ± 8.3	74.2 ± 9.9	80.2 ± 6	p = 0.089024
Last VA (letters)	77.7 ± 8.4	77.5 ± 10.3	77.9 ± 7.1	p = 0.908481
VA gain (loss)		+3.3	-2.3	p = 0.061144



### Possible Mechanism of Action of Hi-Dose Statins in AMD

- ▀ Reduction of local and systemic lipid production
- ▀ Increase viability of macrophages
- ▀ Reducing oxidative damage
- ▀ Reduce inflammatory cytokines, VEGF

### Drusen Reduction in AMD



- ▀ Spontaneous regression
- ▀ Drusen reduction in late stage disease
- ▀ Laser trials (PTAMD)
- ▀ Complement inhibitor 5 trial

### Limitations of Pilot Study

- ▀ Open label, non-randomized
- ▀ Small, homogeneous sample size
- ▀ Short time period (avg 1.5 yrs)
- ▀ Possibility of spontaneous reduction of drusen w/o atrophy
- ▀ How long will effects last?
- ▀ How long should statins be administered?
- ▀ Other dosages? Statin types? AMD types?

### Future Studies With Statins

- ▀ Should take into account genotype and phenotypes
- ▀ Stages of AMD
- ▀ Dosing
- ▀ Lipophilicity and potency of statin
- ▀ Larger, randomized

## Translation of Scientific Data to Optometric Practice When Evaluating Non-Exudative AMD

### Risk assessment

- Genetic and environmental risk factors
- Genetic profiling and testing
- Risk factors
- Clinical evaluation of hi-risk characteristics
- Dark adaptation(Maculogix)
- Cholesterol status?

## Translation of Scientific Data in Optometric Practice When Evaluating Non-Exudative AMD

- Supplementation
  - AREDS II
  - Zinc?
  - Omega-3s?
- Smoking cessation
- Dietary considerations/BMI
- UVA/UVB protection
- Statin discussion with hi-risk patients and primary physicians?

## Future Research of AMD Treatments

- Angiogenesis
  - Port delivery systems
- Neuroprotection
- Biology
  - Lampalizumab(Phase 3)



- Improvements in phenotyping and classification

## References

- Gehlbach P, Li T, Hafez E. Statins for age-related macular degeneration. *Cochrane Database Syst Rev.* 2015; 2: CD009527.
- Guymer RH, Baird PN, Varsamidis M, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. *PLoS One.* 2013; 8: e83759.
- VanderBeek BL, Zacks DN, Tolwar N, Nan B, Stein JD. Role of statins in the development and progression of age-related macular degeneration. *Retina.* 2013; 33: 414-422.
- Cougnard-Gregoire A, Delyfer MH, Karabekir JF, et al. Elevated high-density lipoprotein cholesterol and age-related macular degeneration: the Aterion study. *PLoS One.* 2014; 9: e91973.
- Klein R, Myers CE, Bultmann SK, et al. Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. *Am J Ophthalmol.* 2014; 158: 513-524.
- Rogers SL, Magliano DJ, LeVinson DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. *Clin Ther.* 2007; 29: 242-252.
- Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med.* 1999; 341: 70-76.
- Nissen SE, Tuzcu EM, Schoenfiggen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med.* 2005; 352: 29-38.
- Zhao XQ, Dong L, Hatsukami T, et al. MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. *JACC Cardiovasc Imaging.* 2011; 4: 977-986.
- Vavvas DG, Daniels AB, Kaplala ZG, et al. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. *EBioMedicine.* 2016; 5: 198-203.

- Miller JW. Age-related macular degeneration revisited—piecing the puzzle: the LXIX Edward Jackson memorial lecture. *Am J Ophthalmol*. 2013; 155: 1-33.e13.
- Curcio CA, Johnson M, Rudolf M, Huang JD. The oil spill in ageing Bruch membrane. *Br J Ophthalmol*. 2011; 95: 1638-1645.
- Gellhach P, Li T, Hafef E. Statins for age-related macular degeneration. *Cochrane Database Syst Rev*. 2015; 2: CD010897.
- Guymer RH, Baird PN, Vassanidis M, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. *PLoS One*. 2013; 8: e63759.
- van derBeek BL, Zacks DN, Talwar N, Nan B, Stein JD. Role of statins in the development and progression of age-related macular degeneration. *Retina*. 2013; 33: 414-422.
- Cougnard-Gregoire A, Delvif MN, Karabelnik JF, et al. Elevated high-density lipoprotein cholesterol and age-related macular degeneration: the Alienor study. *PLoS One*. 2014; 9: e90973.
- Klein R, Myers CE, Buitendijk GH, et al. Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. *Am J Ophthalmol*. 2014; 158: 513-524.
- Rogers SL, Magliano DJ, LeVinson DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. *Clin Ther*. 2007; 29: 242-252.
- Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med*. 1999; 341: 70-76.
- Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med*. 2005; 352: 29-38.
- Zhao XQ, Dong L, Hattukami T, et al. MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. *JACC Cardiovasc Imaging*. 2011; 4: 977-986.
- Vavvas DG, Daniels AB, Kapsala ZG, et al. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. *BioMedicine*. 2016; 5: 198-203.

THANK YOU